Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eton Pharmaceutcials Inc (ETON)

Eton Pharmaceutcials Inc (ETON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 634,080
  • Shares Outstanding, K 27,284
  • Annual Sales, $ 79,950 K
  • Annual Income, $ -4,600 K
  • EBIT $ -1 M
  • EBITDA $ 4 M
  • 60-Month Beta 1.19
  • Price/Sales 8.00
  • Price/Cash Flow 4,524.23
  • Price/Book 24.05

Options Overview Details

View History
  • Implied Volatility 82.62% (-3.99%)
  • Historical Volatility 55.58%
  • IV Percentile 37%
  • IV Rank 27.33%
  • IV High 188.51% on 03/05/26
  • IV Low 42.81% on 08/12/25
  • Expected Move (DTE 18) 2.25 (9.98%)
  • Put/Call Vol Ratio 9.50
  • Today's Volume 21
  • Volume Avg (30-Day) 285
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 3,098
  • Open Int (30-Day) 3,154
  • Expected Range 20.33 to 24.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.10
  • Number of Estimates 2
  • High Estimate 0.17
  • Low Estimate 0.03
  • Prior Year 0.07
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.14 +39.94%
on 03/09/26
24.46 -7.69%
on 03/25/26
+5.59 (+32.90%)
since 02/27/26
3-Month
14.27 +58.23%
on 02/05/26
24.46 -7.69%
on 03/25/26
+5.75 (+34.17%)
since 12/26/25
52-Week
11.09 +103.67%
on 04/07/25
24.46 -7.69%
on 03/25/26
+9.56 (+73.43%)
since 03/28/25

Most Recent Stories

More News
These 3 Defensive Stocks Just Hit 52-Week Highs — Should You Lock In Gains?

High PEG ratios indicate that many defensive stocks in health care and consumer staples trade at stretched valuations. With earnings growth lagging price momentum, three stand out as candidates for profit-taking...

DAR : 60.37 (+1.84%)
VLO : 250.27 (-1.59%)
MASI : 177.32 (+0.12%)
ETON : 22.58 (-2.84%)
DHR : 183.89 (+1.31%)
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024 Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS...

ETON : 22.58 (-2.84%)
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...

ETON : 22.58 (-2.84%)
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

HEMANGEOL® is the only FDA-approved treatment for infantile hemangioma HEMANGEOL will be commercialized by Eton beginning May 1 st HEMANGEOL will be distributed through the company’s Eton Cares™...

ETON : 22.58 (-2.84%)
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

DESMODA is the first and only FDA-approved desmopressin oral solution Commercial launch expected on March 9 th DESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing...

ETON : 22.58 (-2.84%)
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...

ETON : 22.58 (-2.84%)
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

Product is currently under review with the FDA Potential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”)...

ETON : 22.58 (-2.84%)
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th

DEER PARK, Ill., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...

ETON : 22.58 (-2.84%)
Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...

ETON : 22.58 (-2.84%)
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19 th straight quarter of sequential product sales growth Q3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP...

ETON : 22.58 (-2.84%)

Business Summary

Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.

See More

Key Turning Points

3rd Resistance Point 24.81
2nd Resistance Point 24.41
1st Resistance Point 23.82
Last Price 22.58
1st Support Level 22.83
2nd Support Level 22.43
3rd Support Level 21.84

See More

52-Week High 24.46
Last Price 22.58
Fibonacci 61.8% 19.35
Fibonacci 50% 17.77
Fibonacci 38.2% 16.20
52-Week Low 11.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.